Tumor Progression of Breast Cancer during Hyperinsulinemic Obesity

Austin C Boese; Sumin Kang

doi:10.1016/j.molmed.2020.01.014

Tumor Progression of Breast Cancer during Hyperinsulinemic Obesity

Trends Mol Med. 2020 Apr;26(4):354-356. doi: 10.1016/j.molmed.2020.01.014. Epub 2020 Feb 13.

Authors

Austin C Boese¹, Sumin Kang²

Affiliations

¹ Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322, USA.
² Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory, Emory University School of Medicine, Atlanta, GA 30322, USA. Electronic address: smkang@emory.edu.

PMID: 32277929
DOI: 10.1016/j.molmed.2020.01.014

Abstract

Factors of metabolic syndrome including hyperinsulinemia and obesity are well known to increase the risk of cancer incidence and progression. In a recent iScience article, Ramos et al. demonstrate a novel tumor-suppressor role of the circadian transcription factor BMAL1 in triple-negative breast cancer (TNBC) specifically under conditions of hyperinsulinemia.

Keywords: BMAL1; insulin treatment; metabolism; obesity; triple-negative breast cancer; tumor suppressor.

Publication types

Comment